Towards an Architecture to Guarantee Both Data Privacy and Utility in the First Phases of Digital Clinical Trials
In the era of the Internet of Things (IoT), drug developers can potentially access a wealth of real-world, participant-generated data that enable better insights and streamlined clinical trial processes. Protection of confidential data is of primary interest when it comes to health data, as medical...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-11-01
|
| Series: | Sensors |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8220/18/12/4175 |
| _version_ | 1818001520675782656 |
|---|---|
| author | Fabio Angeletti Ioannis Chatzigiannakis Andrea Vitaletti |
| author_facet | Fabio Angeletti Ioannis Chatzigiannakis Andrea Vitaletti |
| author_sort | Fabio Angeletti |
| collection | DOAJ |
| description | In the era of the Internet of Things (IoT), drug developers can potentially access a wealth of real-world, participant-generated data that enable better insights and streamlined clinical trial processes. Protection of confidential data is of primary interest when it comes to health data, as medical condition influences daily, professional, and social life. Current approaches in digital trials entail that private user data are provisioned to the trial investigator that is considered a trusted party. The aim of this paper is to present the technical requirements and the research challenges to secure the flow and control of personal data and to protect the interests of all the involved parties during the first phases of a clinical trial, namely the <i>characterization</i> of the potential patients and their possible <i>recruitment</i>. The proposed architecture will let the individuals keep their data private during these phases while providing a useful sketch of their data to the <i>investigator</i>. Proof-of-concept implementations are evaluated in terms of performances achieved in real-world environments. |
| first_indexed | 2024-04-14T03:35:21Z |
| format | Article |
| id | doaj.art-12f37dfe365c4227a05a3d92b042e519 |
| institution | Directory Open Access Journal |
| issn | 1424-8220 |
| language | English |
| last_indexed | 2024-04-14T03:35:21Z |
| publishDate | 2018-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Sensors |
| spelling | doaj.art-12f37dfe365c4227a05a3d92b042e5192022-12-22T02:14:47ZengMDPI AGSensors1424-82202018-11-011812417510.3390/s18124175s18124175Towards an Architecture to Guarantee Both Data Privacy and Utility in the First Phases of Digital Clinical TrialsFabio Angeletti0Ioannis Chatzigiannakis1Andrea Vitaletti2Department of Computer, Control, and Management Engineering “Antonio Ruberti”, Sapienza University of Rome, 00185 Rome, ItalyDepartment of Computer, Control, and Management Engineering “Antonio Ruberti”, Sapienza University of Rome, 00185 Rome, ItalyDepartment of Computer, Control, and Management Engineering “Antonio Ruberti”, Sapienza University of Rome, 00185 Rome, ItalyIn the era of the Internet of Things (IoT), drug developers can potentially access a wealth of real-world, participant-generated data that enable better insights and streamlined clinical trial processes. Protection of confidential data is of primary interest when it comes to health data, as medical condition influences daily, professional, and social life. Current approaches in digital trials entail that private user data are provisioned to the trial investigator that is considered a trusted party. The aim of this paper is to present the technical requirements and the research challenges to secure the flow and control of personal data and to protect the interests of all the involved parties during the first phases of a clinical trial, namely the <i>characterization</i> of the potential patients and their possible <i>recruitment</i>. The proposed architecture will let the individuals keep their data private during these phases while providing a useful sketch of their data to the <i>investigator</i>. Proof-of-concept implementations are evaluated in terms of performances achieved in real-world environments.https://www.mdpi.com/1424-8220/18/12/4175privacy protectionsecurityhuman-centered computingmobile devicesIoTsurveyperformance evaluation |
| spellingShingle | Fabio Angeletti Ioannis Chatzigiannakis Andrea Vitaletti Towards an Architecture to Guarantee Both Data Privacy and Utility in the First Phases of Digital Clinical Trials Sensors privacy protection security human-centered computing mobile devices IoT survey performance evaluation |
| title | Towards an Architecture to Guarantee Both Data Privacy and Utility in the First Phases of Digital Clinical Trials |
| title_full | Towards an Architecture to Guarantee Both Data Privacy and Utility in the First Phases of Digital Clinical Trials |
| title_fullStr | Towards an Architecture to Guarantee Both Data Privacy and Utility in the First Phases of Digital Clinical Trials |
| title_full_unstemmed | Towards an Architecture to Guarantee Both Data Privacy and Utility in the First Phases of Digital Clinical Trials |
| title_short | Towards an Architecture to Guarantee Both Data Privacy and Utility in the First Phases of Digital Clinical Trials |
| title_sort | towards an architecture to guarantee both data privacy and utility in the first phases of digital clinical trials |
| topic | privacy protection security human-centered computing mobile devices IoT survey performance evaluation |
| url | https://www.mdpi.com/1424-8220/18/12/4175 |
| work_keys_str_mv | AT fabioangeletti towardsanarchitecturetoguaranteebothdataprivacyandutilityinthefirstphasesofdigitalclinicaltrials AT ioannischatzigiannakis towardsanarchitecturetoguaranteebothdataprivacyandutilityinthefirstphasesofdigitalclinicaltrials AT andreavitaletti towardsanarchitecturetoguaranteebothdataprivacyandutilityinthefirstphasesofdigitalclinicaltrials |